STATEMENT OF NEED
The introduction of effective antiemetic regimens in recent years has led many clinicians to assume that CINV is no longer a major problem. However, nausea and vomiting are frequent complications of cancer treatment, occurring in up to 80% of patients receiving chemotherapy. Furthermore, wide gaps exist between patient and provider perceptions of nausea and vomiting. Clinicians often consider nausea and vomiting “minor” complications and regard these symptoms as inconveniences rather than serious medical problems. On the contrary, uncontrolled CINV is reported by patients to significantly impair their quality of life and reduce daily functioning. Uncontrolled CINV may also lead to severe clinical conditions, including electrolyte imbalance, dehydration, and malnutrition, which may compromise a patient’s ability to respond to cancer therapy. Additionally, research has shown that uncontrolled CINV may be detrimental to survival. Moreover, the costs associated with uncontrolled CINV represent a significant economic burden to the health care system.
Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of chemotherapy-induced nausea and vomiting (CINV).
Upon completion of this activity, participants should be able to:
Rebecca Clark-Snow, RN, BSN, OCN® (Chairperson)
Una T. Hopkins, DNP
Dickstein Cancer Treatment Center at White Plains Hospital
There is no fee to participate in or claim CE credit for this activity.
Jointly Provided by
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and i3 Health. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
December 22, 2017 – December 21, 2018
No prerequisites are required for this activity.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, and AOCNS® renewal candidates: 1 ILNA point may be applied toward:
Symptom Management ......................................................1 point
BMTCN® renewal candidates: 1 ILNA point may be applied toward:
Post-Transplant Issues ........................................................1 point
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Ms. Clark-Snow discloses that she has served on the speakers bureau for Merck.
Dr. Hopkins discloses that she has served as a consultant for Eisai.
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Merck.